Robert Alexander Ingram Biocryst Pharmaceuticals Inc (BCRX) insider trading activity

Robert Alexander Ingram is Director of BIOCRYST PHARMACEUTICALS INC. Currently has a direct ownership of 100,198 shares of BCRX, which is worth approximately $643,271. The most recent transaction as insider was on Feb 28, 2023, when has been sold 2,259 shares (Common Stock) at a price of $8.85 per share, resulting in proceeds of $19,992. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 100K

0% 3M change

0% 12M change

Total Value Held $643,271

ROBERT ALEXANDER INGRAM Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 28 2023	BUY Grant, award, or other acquisition	$19,992 $8.85 p/Share	2,259 Added 2.2%	100,198 Common Stock
Nov 30 2022	BUY Grant, award, or other acquisition	$19,999 $13.36 p/Share	1,497 Added 1.51%	97,939 Common Stock
Aug 31 2022	BUY Grant, award, or other acquisition	$19,988 $13.9 p/Share	1,438 Added 1.47%	96,442 Common Stock
Jun 07 2022	BUY Grant, award, or other acquisition	-	12,866 Added 11.93%	95,004 Common Stock
May 31 2022	BUY Grant, award, or other acquisition	$19,346 $9.31 p/Share	2,078 Added 2.47%	82,138 Common Stock
Feb 28 2022	BUY Grant, award, or other acquisition	$18,736 $16.61 p/Share	1,128 Added 1.39%	80,060 Common Stock
Nov 30 2021	BUY Grant, award, or other acquisition	$18,741 $12.06 p/Share	1,554 Added 1.93%	78,932 Common Stock

Aug 31 2021	BUY Grant, award, or other acquisition	$18,738 $15.92 p/Share	1,177 Added 1.5%	77,378 Common Stock
May 28 2021	BUY Grant, award, or other acquisition	$18,735 $15.77 p/Share	1,188 Added 1.54%	76,201 Common Stock
Feb 26 2021	BUY Grant, award, or other acquisition	$18,746 $10.78 p/Share	1,739 Added 2.27%	75,013 Common Stock
Nov 30 2020	BUY Grant, award, or other acquisition	$18,749 $5.11 p/Share	3,669 Added 4.77%	73,274 Common Stock

Also insider at

BDTX

Black Diamond Therapeutics, Inc. Healthcare

RAI